Aug. 14 - ‘Breathing room’ for Sarepta, an early M&A signal and a microbiome drug setback

Vedanta, PureTech’s microbiome startup, to cut staff after study setback; Biotech’s M&A outlook is uncertain. Track the deals that are happening here.; With FDA PreCheck, drugmakers may get a manufacturing boost

View online | Signup

Daily Dive

Aug. 14, 2025 | Today’s news and insights for biopharma leaders

src="https://cdn.doubleverify.com/dvbm.js#ctx=14097043&cmp=32790685&sid=6553407&plc=420282760&advid=5549904&adsrv=1&mon=1&blk=0">

BROUGHT TO YOU BY — Fidelity Investments

Give your equity program an edge

As your business grows, Fidelity is there to help with equity management solutions to meet your needs, from startup to IPO and beyond. Put our experience to work.

Sarepta sells Arrowhead shares as partnership, debt payments loom

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as “additional breathing room” ahead of a debt maturity in 2027.

Vedanta, PureTech’s microbiome startup, to cut staff after study setback

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target of Vedanta and other companies like it.

UPDATED

Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

Eight of the last 11 M&A deals and 17 of the 26 so far this year have involved public biotech companies, a reversal from last year when startups were more frequently the target of acquisitions.

A comparison of public and private biotechnology company acquisitions worth at least $50 million upfront, by quarter.

Credit: Ben Fidler / BioPharma Dive

Regulatory uncertainty and access challenges changing go-to-market models, DTC and DTP

DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

With FDA PreCheck, drugmakers may get a manufacturing boost

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

GSK's Strategic Shift: Unlocking Drug Success

GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.

Watch Now

From Our Library

Trendline